Editas Medicine Inc. [EDIT] stock was sold by ROBERTSON MICHELLE at the price of US$2882.0

0
3

In a filing, Editas Medicine Inc. revealed its EVP, CHIEF FINANCIAL OFFICER ROBERTSON MICHELLE unloaded Company’s shares for reported $2882.0 on Sep 06. In the deal valued at $15.01 per share,192 shares were sold. As a result of this transaction, ROBERTSON MICHELLE now holds 82,475 shares worth roughly $ 0.91 million.


Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report

Sponsored


Then, Eaton Bruce sold 101 shares, generating $1,516 in total proceeds. Upon selling the shares at $15.01, the EVP, CHIEF BUSINESS OFFICER now owns 65,027 shares.

Before that, Eaton Bruce sold 293 shares. Editas Medicine Inc. shares valued at $5,449 were divested by the EVP, CHIEF BUSINESS OFFICER at a price of $18.60 per share. As a result of the transaction, Eaton Bruce now holds 65,128 shares, worth roughly $0.72 million.

BofA Securities initiated its Editas Medicine Inc. [EDIT] rating to a Neutral in a research note published on Monday, September 29, 2022; the price target was $18. PT values the company’s stock at a premium of 38.67 to its Monday closing price. A number of analysts have revised their coverage, including SVB Leerink’s analysts, who began to cover the stock in mid October with a ‘”a Mkt perform”‘ rating. Stifel began covering EDIT with “Hold” recommendation on September 24, 2021. Oppenheimer revised its rating on September 10, 2021. It rated EDIT as “an Outperform” which previously was an “a Perform”.

Price Performance Review of EDIT

On Monday, Editas Medicine Inc. [NASDAQ:EDIT] saw its stock fall -4.00% to $11.04. On the same session, the stock had its day’s lowest price of $10.89, but rose to a high of $11.74. Over the last five days, the stock has lost -12.03%. Editas Medicine Inc. shares have fallen nearly -58.42% since the year began. Nevertheless, the stocks have fallen -70.56% over the past one year. While a 52-week high of $42.11 was reached on 01/03/22, a 52-week low of $9.59 was recorded on 06/14/22. SMA at 50 days reached $13.16, while 200 days put it at $14.85. A total of 1.28 million shares were traded, compared to the trading of 2.29 million shares in the previous session.

Levels Of Support And Resistance For EDIT Stock

The 24-hour chart illustrates a support level at 10.71, which if violated will result in even more drops to 10.37. On the upside, there is a resistance level at 11.56. A further resistance level may holdings at 12.07. The Relative Strength Index (RSI) on the 14-day chart is 38.82, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.52, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 95.51%. Stochastics %K at 13.23% indicates the stock is a buying.

How much short interest is there in Editas Medicine Inc.?

A steep rise in short interest was recorded in Editas Medicine Inc. stocks on Jul 14, 2022, growing by 1.76 million shares to a total of 16.38 million shares. Yahoo Finance data shows the prior-month short interest on Jun 14, 2022 was 14.62 million shares. There was a rise of 10.74%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 26.77% of the overall stock float, the days-to-cover ratio (short ratio) rose to 7.93.

Editas Medicine Inc. [EDIT] – Who Are The Largest Shareholders?

In filings from SSgA Funds Management, Inc., it is revealed that the company now owns 7,879,890 shares, or roughly 11.46% of the outstanding EDIT shares. In other words, the investor’s shares have risen by 2,399,852 from its previous 13-F filing of 5480038.0. Additionally, The Vanguard Group, Inc. decreased -2.50% of its stake after which the total value it holdings stand at $79,857,163, while BlackRock Fund Advisors added 6.40% of its stake to hold $65.5 million in the firm. Over the last quarter, Geode Capital Management LLC purchased 90,284 shares of Editas Medicine Inc., while JPMorgan Asset Management bought -36,504 shares. At present, Capital Research & Management Co is holding 1,100,000 shares valued at $13.46 million. Woodline Partners LP owned 1,016,891 shares of the company at the time of its most recent 13F filing, worth $12.45 million.

According to FactSet, Editas Medicine Inc.’s share price will average $26.20 in the next year, based on opinions of analysts polled by the firm. This is up nearly 56.52 percent from its previous closing price of $11.50. Analysts expect Editas Medicine Inc. stock to reach the higher price of $80.00, while the lowest price estimate is $8.00. However, 18 analysts have rated EDIT stock as a Hold in their predictions for 2022.

LEAVE A REPLY

Please enter your comment!
Please enter your name here